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Abstract
Background: Dengue viruses (DENV) are one of the most important viral diseases in the world with approximately
100 million infections and 200,000 deaths each year. The current lack of an approved tetravalent vaccine and
ineffective insecticide control measures warrant a search for alternatives to effectively combat DENV. The trans-
splicing variant of the Tetrahymena thermophila group I intron catalytic RNA, or ribozyme, is a powerful tool for
post-transcriptional RNA modification. The nature of the ribozyme and the predictability with which it can be
directed makes it a powerful tool for modifying RNA in nearly any cell type without the need for genome-altering
gene therapy techniques or dependence on native cofactors.
Results: Several anti-DENV Group I trans-splicing introns (aDENV-GrpIs) were designed and tested for their ability
to target DENV-2 NGC genomes in situ. We have successfully targeted two different uracil bases on the positive
sense genomic strand within the highly conserved 5’-3’ cyclization sequence (CS) region common to all serotypes
of DENV with our aDENV-GrpIs. Our ribozymes have demonstrated ability to specifically trans-splice a new RNA
sequence downstream of the targeted site in vitro and in transfected insect cells as analyzed by firefly luciferase
and RT-PCR assays. The effectiveness of these aDENV-GrpIs to target infecting DENV genomes is also validated in
transfected or transformed Aedes mosquito cell lines upon infection with unattenuated DENV-2 NGC.
Conclusions: Analysis shows that our aDENV-GrpIs have the ability to effectively trans-splice the DENV genome
in situ. Notably, these results show that the aDENV-GrpI 9v1, designed to be active against all forms of Dengue
virus, effectively targeted the DENV-2 NGC genome in a sequence specific manner. These novel aDENV-GrpI
introns provide a striking alternative to other RNA based approaches for the transgenic suppression of DENV in
transformed mosquito cells and tissues.
Background
The mosquito-borne Dengue viruses (DENV) are
responsible for approximately 100 million infections and
200,000 deaths each year with 2.5 billion people remain-
ing at risk for DENV infection, making DENV one of
the most important viral diseases in the world (1). Infec-
tion with one of four antigenically distinct, but related
Dengue virus serotypes (designated DENV 1 through 4)
can result in Dengue fever (DF) and/or Dengue hemor-
rhagic fever (DHF) [1]. DF and DHF are endemic to tro-
pical and subtropical regions of the world, but global
changes in climate, rapid dispersal of virus due to
ease of global travel, and migration of humans to non-
tropical regions has resulted in DENV outbreaks in
areas that were once non-endemic to the Dengue
viruses [2,3]. Modern travel and shipping inevitably
leads to an increase in the number of cases in developed
countries as well, including a recent outbreak in the
Hawaiian islands in 2001 (Source: CDC). These viruses
are maintained in a cycle that involves humans as well
as the dipteran Aedes aegypti mosquito which preferen-
tially feeds on human blood and is widely distributed
throughout the world [2,3].
The current lack of an approved effective tetravalent
vaccine and the ineffectiveness of insecticide control
measures continue to warrant a search for alternative
* Correspondence: fraser.1@nd.edu
1Eck Institute for Global Health, Department of Biology, University of Notre
Dame, Notre Dame, IN, USA 46556
Full list of author information is available at the end of the article
Carter et al. BMC Molecular Biology 2010, 11:84
http://www.biomedcentral.com/1471-2199/11/84
© 2010 Carter et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.strategies to effectively combat DENV. Newer approaches
that have received considerable attention include
interference with the extrinsic incubation cycle of
DENV replication within the arthropod vector [2,3].
One such approach envisions population replacement
of vector competent mosquitoes with those refractory
for infection and/or transmission of the virus, which
could theoretically halt disease transmission [2,3].
This approach has distinct advantages for environ-
mental safety, cost effectiveness, and long term dis-
ease suppression.
Our lab has been exploring anti-DENV ribozyme stra-
tegies for intracellular suppression of virus infection as a
means of transgenic immunization of mosquitoes. In a
previous report we examined the effectiveness of ham-
merhead ribozymes in suppressing DENV infection in
retrovirus transduced mosquito cells [4]. While we iden-
tified several ribozymes that are effective in significantly
reducing DENV 2-NGC infection of Ae. albopictus C6/
36 cells, our inability to target sequences that are con-
served among all serotypes require investigation of addi-
tional ribozymes with potential for wider specificity. As
an alternative strategy we are investigating the feasibility
of utilizing a Group I intron trans-splicing strategy to
target highly conserved sequences within the DENV
genome.
The trans-splicing reaction of the Group I intron is
derived from the natural cis-splicing reaction. Both the
cis and trans-splicing reaction can be divided into two
distinct successive transesterification steps [5]. The pri-
mary difference between the two reactions is that while
the cis-splicing reaction occurs along one continuous
RNA molecule to join a 5’ and a 3’ exon, the trans-spli-
cing intron is located on the same molecule as the 3’
exon, but seeks out a separate 5’ exon to which it can
append the 3’ exon [6].
The engineered trans-splicing activity of the Group I
intron is a versatile tool with respect to the ‘editing’ of
RNA [7-17]. Group I intron trans-splicing has been used
in a number of applications, such as: repair of mutant
a-globin mRNA [8], restoration of wild-type p53 activity
in three cancerous cell lines [18], re-establishment of the
function of the canine skeletal muscle chloride channel
[19], and induction of p16 activity in a pancreatic
cell line [10]. More applicable to our research is the
trans-splicing group-I intron targeting of the HIV-1 tat
[20], cucumber mosaic virus coat protein mRNAs [7],
and the hepatitis C virus internal ribosome entry site
(HCV-IRES) [21].
Group I introns are subject to the same limitations as
antisense or RNAi methods of RNA suppression because
the high mutation rate of the DENV genome promotes
the spread of strains capable of avoiding the antisense
recognition essential to the trans-splicing reaction.
Approaches that inhibit DENV infection by direct inter-
action with the RNA genome must be designed to act
upon invariant sequences to be effective. The most
invariant segments of the DENV genome are the 5’ and
the two 3’ cyclization sequences (5’C S ,C S 1 ,a n dC S 2
respectively) which are involved in the formation of a
panhandle structure that is apparently essential for gen-
ome replication [22,23]. These cyclization sequences are
separated by such a large intervening length of RNA
that they are effectively acting in a trans manner, and
since they are able to base-pair with each other their
secondary structure is likely open and conducive to
base-pairing.
The 5’CS is located downstream of the polyprotein
start codon, well within the ORF of the Capsid (CA)
protein. The stringency of tolerable mutations in this
sequence may be increased by the need of the virus to
conserve a functional CA protein. In fact, all mosquito-
borne flaviviruses share an 8 bp stretch of nucleotides
within this 5’ CS sequence [24].
In this study we designed Group I introns to target
and catalyze trans-splicing within the conserved
sequences of the 5’ CS region of DENV. These introns
cleave either single stranded or homologously paired
double stranded RNA at defined uracils and covalently
join a 3’ exon tag to the end of the cleavage product.
We evaluated these introns for activity in both trans-
fected and transformed cell cultures to determine their
effectiveness in targeting DENV sequences. Two of
these introns, designed 9v1 and 96v4 gave the greatest
number of trans-splice product compared to the other
Anti-DENV Group I trans-splicing introns (aDENV-
GrpI) in each respective series, as judged by luciferase
assays. The success of this approach against both subge-
nomic DENV sequences and infecting DENV genomes
provides a potent anti-viral strategy that should prove
useful against this important disease.
Results
Analysis of highly conserved elements in the Dengue
genome
All nucleotide position designations used throughout the
study are relative to the published DENV- 2 New
Guinea strain C genome (DENV-2 NGC; GenBank
Accession: M29095). We began by aligning all 98 DENV
genomes and genome fragments from the four different
serotypes that were present in GenBank using the Clus-
talX program. While overall similarity was highest
within a given serotype, the alignment showed a signifi-
cant conserved region between 131 and 164 nt having
only one variable base at position 152 nt (Figure 1a).
This sequence was wholly contained within the Capsid
protein gene, and overlapped with the 5’CS identified as
essential for replication [23,25].
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(aDENV-GrpIs) targeting conserved DENV sequences
The Group I intron requires an accessible uracil nucleo-
tide downstream of which the target sequence is
cleaved. In a trans-splicing reaction, two separate seg-
ments of the intron are utilized to specify the RNA
sequence the ribozyme targets. The internal guide
sequence (IGS), a part of the P1 helix, and external
guide sequence (EGS) are each complementary to the
target RNA sequence (Figure 1c step 1 and Figure 2).
The IGS is limited in size to 9 base pairs near the
reactive uracil while the EGS can be of any length and
forms a transient helix with the target RNA sequence
downstream of the reactive uracil [20]. Biochemical ana-
lysis has shown that the activity of Group I introns can
be enhanced through 5’-a n d3 ’-splice junction base
pairing [26].
Trans-splicing group I introns promote the joining of
a target sequence to a 3’ exon through two successive
yet independent trans-splicing reactions (Figure 1c; [6]).
The IGS and EGS of the aDENV-GrpI form Watson-
Crick base pairs with the DENV 2-NGC target RNAs.
Figure 1 aDENV-GrpI targeting and trans-splicing of DENV. Schematic diagrams showing DENV sequences targeted by 9 series (A) and 96
series (B) aDENV-GrpIs (shown as blow-ups), and the trans-splicing reaction mediated by these introns (C) as previously described for other
trans-splicing ribozymes (5). A) A region of the DENV genome targeted by the 9 series intron is conserved among all serotypes based on Clustal
X DENV genome alignment of all 98 DENV sequences deposited at GenBank. All accession numbers are listed in Methods. Shaded areas indicate
100% conserved bases. The arrows designate U residues targeted for cleavage. The residues contributing to structural elements of the intron
RNA-target RNA complexes in the different 9 series introns are as follows: Internal Guide Sequence (IGS) = U138 to A146, Bulge Loop (BL) =
A147 to A 152, and External Guide Sequence (EGS) = G153 to G161 as indicated on. Uracil 143 is targeted for cleavage. The single adenine at
base 152 is not fully conserved and has therefore been engineered into LB, which is not required to base pair with the target for efficient
splicing. B) Primary sequence of the DENV 2-NGC genome depicting the residues contributing to structural elements of the intron RNA-target
RNA complexes in the different 96 series intron structures: IGS = A127 to C135, LB = A136 to A 139, and EGS = U140 to U235. The uracil at
position 132 is targeted for cleavage. C) The aDENV-GrpI- mediated trans-splicing reaction. The DENV target sequence is represented as the
upper schematic diagram with the trans-splicing ribozymes shown below. See text for description. Figure not drawn to scale.
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by an exogenously inserted UAA stop codon immedi-
ately upstream of the UCG splice site. An initial transes-
terification reaction results in cleavage of the target
RNA in a guanoisine dependent manner with conforma-
tional change of the EGS. Displacement of the distal
portion of the P1helix by sequences upstream of the 3’
exon forms the P10 helix, allowing a second transesteri-
fication reaction to take place. This results in ligation of
the DENV 2 NGC genome to the FL 3’exon, promoting
firefly expression from the DENV capsid AUG.
While most strategies for identifying optimal IGS
sequences utilize a randomized library, called a GN5
library, to locate the most accessible uracil within a
given target sequence [27,28], our approach for targeting
as p e c i f i cs e g m e n to ft h eD E N Vg e n o m ew i t h i nt h e
DENV 5’ conserved region limited our choices of ura-
cils, and the GN5 library approach was not an option.
We therefore employed a more direct approach for our
analyses.
Anti-DENV Group I trans-splicing introns (aDENV-
GrpIs) were designed to target two different uracil bases
within the identified conserved region. The first set of
introns targeted uracil 143 (U143) and were designed to
effectively trans-splice all known DENV sequences (Fig-
u r e1 a ) .A l lo ft h e s ei n t r o n si n c l u d e da9n ta n t i s e n s e
External Guide Sequence (EGS) targeting downstream
sequences that are also conserved among all DENV gen-
omes to improve the targeting capability of the intron
and to minimize potential off-target splicing interac-
t i o n s .As i n g l ev a r i a b l eb a s ea tn t1 5 2i sp o s i t i o n e d
within a non-homologous bulge loop structure that
separates the IGS and EGS, and therefore does not
influence the targeting of the intron (Figure 2). This
bulge loop structure allows the formation of the P10
helix which increases the catalytic efficiency of the
intron [29].
Intron 9v1 was made with a 9 base P1 helix, and a 9
base EGS (Additional file 1). Excluding the wobble base
at position U143 which is required for proper cleavage
[30-33], 17 bases of this intron interact directly with the
intended target sequence.
A second set of aDENV-GrpIs were constructed with
an extended 96 base antisense EGS that was engineered
to specifically bind to the DENV-2 NGC (Figure 1b).
Each version of this series shared the same EGS and P1
helix, and targeted the same uracil, U132, but differed in
their P10 helix. The first version of the 96 series, 96v1,
was made with a 6 base pair P10 helix that had no wob-
ble base, and a standard P1 helix of 9 bases, inclusive of
t h er e q u i r e dw o b b l eb a s e( A d ditional file 1). 96v3 is
similar to 96v1 in all respects except the trimming of 3
nucleotides between the P10 helix region and the cataly-
tic core. Finally, version 4 of the 96 series (96v4) incor-
porated a wobble base pairing downstream of the 3’
exon splice-site. This alteration in the P10 helix has
been used in published experiments with other group I
introns [9]. The 96 series of introns target a different
uracil than 9 due to the larger stretch of 100% con-
served sequence available for base pairing in the Dengue
2 alignment, thus the reason for the differences in the
nucleotide content of the IGS and nucleotide content
and length of the EGS sequences.
Assessing aDENV-GrpI activity by firefly luciferase assay
in S2 cells
Since each aDENV-GrpI was constructed with a 3’ firefly
luciferase (FL) ORF (Figure 3a), we were able to utilize a
standard dual luciferase assay to assess the ability of each
aDENV-GrpI to target the 5’CS region and form a
DENV2-FL splice product. The formation of this func-
tional splice product can be used to quantitatively gauge
the ability of our anti-DENV group I introns to reprogram
a target sequence either in the form of a double-stranded
fold back mimic, or in the context of DENV infection.
Drosophila S2 cells were co-transfected with aDENV-
GrpI expression plasmids possessing FL as the 3’ exon,
dsDENV-2 substrate expression plasmids, and a Renilla
luciferase expression plasmid, pA5c-IRL, to normalize
the readings (Figure 3b). As a negative control, cells
were co-transfected with the pUC57 empty vector as a
substitute for the substrate, at the same concentration
as the dsDENV-2 concentration used in the experimen-
tals. S2 cells were harvested 48 hours post-transfection,
processed and analyzed as described in Methods. All
Figure 2 Anatomy of trans-splicing group I introns.T h eI G S
forms the P1 helix with the target to bring it into proximity with
the GNP 3’-OH. The EGS is an extra stretch of antisense RNA that
improves the efficiency and specificity of intron targeting the
desired viral sequence. The formation of the P10 helix brings the
newly cleaved 3’-OH of the uracil into proximity with the 3’ exon,
allowing covalent splicing. P1 and P10 overlap by 2 bp IGS upon
targeting of the DENV-2 genome. A UAA stop codon was inserted
in the trans-splicing domain of each intron immediately upstream
of the UCG splice site to prevent inadvertent translation of the 3’
exon until formation of the DENV 2-FL spliced product. The sites of
trans-esterification on the phosphodiester backbone (1 and 2) are
marked with black arrows.
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therefore successful targeting of the pA5c-D2-EYFP-D2
construct. aDENV-GrpI 96v4 produced the greatest
amount of luciferase activity, and therefore the greatest
amount of trans-spliced product, of all the 96 intron
series studied (Figure 3b). The aDENV-GrpI as9v1,
designed to target all DENV serotypes, also produced
significant FL activity verifying its ability to attack our
DENV mimic in these cells.
Engineering and assessment of bicistronic aDENV-GrpI
9v1 and 96v4 intron constructs in Drosophila S2 cells
Since aDENV-GrpIs 9v1 and 96v4 were determined to
be the best candidate introns of each series by the
in vitro assay we assessed the activities of these introns
in transfected cell culture assays. Each of the introns
was tagged downstream of the 3’ exon with the
mCherry fluorescent marker gene expressed from an
IRES sequence of either the Black queen cell virus
(BQCV) or Drosophila C virus (DCV) (Figure 4a).
These Dicistrovirus IRES sequences were previously
determined to yield the highest levels of expression in
Ae aegypti mosquito and D. melanogaster S2 cells [34].
This bi-cistronic configuration allowed monitoring for
the presence and expression of the aDENV-GrpI con-
structs within cell cultures. As expected, IRES-
mediated expression of the mCherry fluorescent mar-
ker occurred upon transfection of these bi-cistronic
constructs in S2 cells (Figure 4b.).
We examined the potential influence addition of the
IRES-mCherry configuration had on aDENV-GrpI activ-
ity by performing dual luciferase assays (see Methods)
with our bicistronic aDENV-GrpIs 9v1 and 96v4 intron
constructs in transient transfected cell culture (Figure
5a). D. melanogaster S2 cells were transiently transfected
with aDENV GrpI 9v1 or 96v4 either unlinked or linked
to an IRES/mCherry driver, and were challenged with a
double-stranded fold back construct designed to mimic
the 5’-3’ CS region of DENV-2 (dsDENV-2; see Meth-
ods) in the presence of the pA5c-IRL normalizer. To
rule out non-specific targeting of the anti-DENV introns
to cellular targets, control cells were transfected with
the pUC57 plasmid in lieu of the dsDENV-2 construct.
FL activity was greatest for the 96v4 IRES-mCherry-
linked or unlinked constructs in S2 cells (Figure 5a),
with no statistical differences in activities among the
96v4 intron constructs. This confirms that addition of
the 3’ IRES/mCherry configuration does not alter the
trans-splicing capabilities of the 96v4 intron, since
equivalent FL counts were obtained for both 96v4 and
96v4 IRES/mCherry constructs.
Similarly, the overall activities of the 9v1 intron con-
structs, whether IRES-mCherry linked or unlinked, were
statistically similar. However, the overall levels of activa-
tion were substantially lower than those detected in cells
expressing 96v4 introns, possibly due to the shorter EGS
[7] target accessibility leading to a decrease in the pro-
duction of trans-spliced product.
aDENV-GrpIs 9v1 or 96v4, IRES-mCherry linked or
unlinked, were either transiently or stably expressed in S2
cells, and analyzed by RT-PCR 72 hours post-transfection
with the dsDENV-2 target plasmid using heterologous pri-
mers (see Methods). Splice product bands were excised,
gel purified, and sequenced to confirm their identity. The
specific DENV-FL splice product was detected by RT-PCR
in transfections with both aDENV-GrpI 9v1 and 96v4 in
S2 cells as evidenced by the presence of a 580 bp band, no
splice product was detected in the absence of the target
dsDENV-2 expression plasmid (Figure 6a and 6b).
aDENV-GrpIs effectively target DENV-2 NGC in mosquito
cells
The effectiveness of our aDENV-GrpI introns to target
infecting DENV genomes was assessed by FL assays
Figure 3 Quantitative luciferase analysis of aDENV-GrpIs
splicing efficiency. A) Schematic diagram of the aDENV-GrpI-FL
constructs used for this analysis. A5c = Drosophila melanogaster
actin 5c promoter, FL = firefly luciferase. B) Drosophila S2 cells were
co-transfected with 3 μg aDENV-GrpIs, 0.5 μg of the IRL expression
plasmid, and 1 μg of either double-stranded DENV-2 target (+) or
control plasmid, pUC57 (-) (see Methods). Following cell lysis,
samples were processed using the Dual Luciferase System
(Promega) according to the manufacturer’s direction. The error bars
represent standard deviations of three independent experiments.
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transiently transfected with aDENV-GrpI introns (Fig-
ure 5b). aDENV-GrpI and pA5c-IRL expression plas-
mids were co-transfected into Aag2 cells, and were
challenged with DENV-2 NGC at an MOI of 0.01 24 h
post transfection. Control cells were transfected with an
empty pUC57 plasmid, in place of the plasmids and
challenged with virus in the same manner. Each of the
aDENV-GrpIs displayed levels of FL activity indicating
successful splicing against the infecting DENV. In this
case FL activity was only slightly greater for the 96v4
IRES-mCherry-linked or unlinked constructs in Aag2
cells, with no statistical differences in activities among
the 96v4 intron constructs. Similarly, the overall
activities of the 9v1 intron constructs, whether IRES-
mCherry linked or unlinked, were statistically similar.
As seen in the previous assays, the overall levels of acti-
vation were somewhat lower than those detected in cells
expressing 96v4 introns most likely due to the shorter
EGS [7] or target accessibility. This confirmed the activ-
ity of our aDENV-GrpIs against actual infecting virus,
and demonstrated that addition of the 3’ IRES/mCherry
configuration does not appear to alter the ability of the
aDENV-GrpIs tested to target DENV genomes in cells.
The overall levels of luciferase activity were lower in
these virally infected mosquito cells than those observed
in S2 cells transfected with a plasmid construct expres-
sing an artificial target sequence. This may be due to
Figure 4 Engineering and fluorescence microscopy of aDENV-GrpIs in a Bicistronic Plasmid. A) Each of the trans-splicing aDENV-GrpI was
tagged downstream of the firefly (FL) 3’ exon with the mCherry fluorescent marker gene expressed from an IRES sequence of either the Black
Queen Cell Virus (BQCV) or Drosophila C Virus (DCV). Expression of these constructs was driven by the Drosophila melanogaster Actin 5c
promoter. This bi-cistronic configuration allowed monitoring for the presence and expression of the aDENV-GrpI constructs within cell cultures.
A5c = Drosophila melanogaster actin 5c promoter, IRES = DCV or BQCV Internal ribosome entry site. B) Expression of mCherry was verified for
each construct by transfecting 1 ug of plasmid DNA into C6/36 cells and examining at 48 hours post transfection. Photographs were taken
under 40× magnification.
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tein expression, or may be due to potential basic differ-
ences in nascent RNA and protein expression between
these two cell lines.
Transient transfection of 9v1, 96v4 and inactive ribo-
zymes Δ9a n dΔ96 was performed in C6/36 cells fol-
lowed by RT-PCR analysis to confirm the detection of
splice product (Figure 7a). No splice product was
observed in the presence of the inactive ribozymes Δ9
and Δ96 showing that the splice product detected is due
to the trans-splicing activities of the aDENV-GrpIs.
Since aDENV- GrpIs 9v1 and 96v4 were determined
to effectively target DENV genomes in transiently trans-
fected cells, we assessed the activities of these introns in
transformed mosquito cell culture assays (Figure 7b). To
produce Ae. albopictus C6/36 cells transformed with
each bicistronic aDENV-GrpI intron construct, cells
were co-transfected with each aDENV-GrpI construct
and a plasmid possessing the hygromycin resistance
gene. Transfection media was replaced with selective
media at 48 hours post transfection. Cells were then
passaged several times per week in selection media. The
concentration of hygromycin used was increased with
each passage until a final concentration of 10 mg/ml
was reached. mCherry fluorescence and RT-PCR were
used to confirm expression of the introns in the trans-
formed cultures.
aDENV-GrpIs 9v1 and 96v4 linked to either the
BQCV or DCV IRES elements expressing mCherry were
stably expressed in Ae. albopictus C6/36 cells and
Figure 5 Assessment of aDENV-GrpI bicistronic constructs
activities using luciferase assays.A )Drosophila S2 cells were co-
transfected with 3 μg of each aDENV-GrpI, 1 μg double-stranded
DENV-2 target (+) or control plasmid (-), and 0.5 μg of IRL
expression plasmids. Following cell lysis, samples were processed
and assayed for luciferase activity (see Methods). The error bars
represent standard deviations of three independent experiments. B)
Aag2 cells co-transfected with aDENV-GrpI and pA5c-IRL expression
plasmids were challenged with DENV-2 NGC at an MOI of 0.01 24 h
post transfection (+). Control cells were transfected with an empty
pUC57 plasmid (-) and challenged with virus in the same manner.
The error bars represent standard deviations of three independent
experiments. B = BQCV IRES. D = DCV IRES. RL = Renilla luciferase.
RLU = Relative Luciferase Units.
Figure 6 aDENV-GrpI constructs effectively target DENV-2 NGC. T-25 flasks containing D. melanogaster S2 cells (5 × 10
5) transiently
transfected (A) or transformed (B) with aDENV-GrpI bicistronic constructs, were transfected with double-stranded DENV-2 target (+), or the
negative control pUC57 empty vector (-). Resulting RNAs were analyzed by RT-PCR in the presence (+Rt) or absence (-Rt) of reverse transcriptase
to insure that observed amplified products were derived from RNA. A PCR amplification product derived from a constructed spliced sequence
control (Methods) is provided as size standard for each gel (DNA+Ctrl). Arrows indicate the predicted size of the principle splice products
resulting from intron activity. The identity of splice product was confirmed by sequencing.
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post transfection. Control cells were transfected with an
empty pUC57 plasmid and challenged with virus in the
same way (Figure 7b).
Cells were processed and analyzed by RT-PCR 4 days
post-infection with heterologous primers to detect the
DENV-FL splice product, and identified bands were
excised, gel purified, and sequenced to confirm their
identity. DENV-2-FL splice product was detected in C6/
36 cells when introns were expressed in a transformed
cell manner, and whether the intron was linked with
either IRES-mCherry configuration (Figure 7b). No con-
trol DENV-2-FL splice product was detected by RT-
PCR in cells transfected with the pUC57 control vector.
Significantly, these results also show that the 9v1 intron,
designed to be active against all forms of Dengue virus,
is capable of effectively targeting the DENV 2-NGC gen-
ome in a sequence specific manner.
Expression of aDENV-GrpIs 9v1 and 96v4 in mosquito
cells leads to suppression of DENV-2 NGC
The final step in our analysis of these aDENV-GrpI
constructs was to determine their ability to suppress
overall infectious DENV-2 NGC production in cell cul-
ture using tissue culture infectious dose immunofluores-
cence antibody (TCID50-IFA) assays (Figure 7c; [4]).
aDENV-GrpI-FL constructs were stably expressed in
C6/36 cells, challenged with DENV-2 NGC, and assayed
as described in Methods. aDENV-GrpIC6/36 cell lines
9v1 and 96 v4 displayed vast reductions in viral titer, up
to 3 log, when compared to the infection control (I).
Suppression of virus replication is evident regardless of
whether the intron expressed in the cells was the 96v4
trans-splicing intron, engineered to specifically target
DENV-2, or the 9v1 trans-splicing intron, which was
designed to target all Dengue virus serotypes. This anti-
viral effect was independent of the IRES-mCherry con-
figuration used in the anti-DENV constructs. Though
the 96v4 intron appeared to suppress DENV-2 NGC
replication to a greater extent than 9v1, a direct com-
parison of activities cannot be considered valid since
aDENV-GrpIs 9v1 and 96v4 target different uracils (4).
Discussion
Like other Flaviviruses, DENV enter the cell by receptor
mediated endocytosis ([35,36]; RME)). Following acidifi-
cation of the endosome and membrane fusion the 9.6
kb positive-sensed DENV genome is released into the
cytoplasm where replication begins. This is an ideal
place for a trans-splicing ribozyme to attack the DENV
genome. One strategy currently under development to
directly attack the Dengue genome is the use of the
RNAi response in mosquitoes [37-42]. It is logical to
assume that the wild-type RNAi response mounted by
the mosquito itself in reaction to an infection is not
strong enough to protect against the spread of the virus,
or Dengue would cease to be a concern. However, pre-
priming mosquito cells for RNAi protection against
Dengue through the expression of Dengue-specific
dsRNA before any infection occurs is an effective
approach, severely hindering replication of the virus in
some cases [39]. As efficient as it is, this tactic suffers
from the same drawbacks as the vaccine: escape
mutants. The error rate of the Dengue RNA polymerase
suggests that, on average, one random mutation arises
Figure 7 aDENV-GrpI -FL constructs effectively target and
suppress DENV-2 in mosquito cells. A) Confirmation of
representative aDENV-GrpI trans-splicing activities. Ae. Albopictus C6/
36 cells were transiently transfected with trans-splicing aDENV-GrpI
bicistronic vector constructs. Resulting RNAs were analyzed by RT-
PCR in the presence (+Rt) or absence (-Rt) of reverse transcriptase
to insure observed amplified products were derived from RNA. A
PCR amplification product derived from a constructed spliced
sequence control (Methods) is provided as a size standard for each
gel (DNA+Ctrl). Δ9 and Δ96 refer to Pabc5 deletion mutations
located in the trans-splicing domain of the group I intron. These
deletions are designed to knock out function providing an
adequate negative control [52]. Arrows indicate the predicted size
of the principle splice products resulting from intron activity. The
identity of spliced product was confirmed by sequencing. B) C6/36
cells were transformed with trans-splicing aDENV-GrpI bicistronic
vector constructs and maintained under 10 mg/ml hygromycin
selection for more than 30 doublings. Transformed cells were
washed twice in serum free media at 15 hours post plating,
infected with DENV-2 NGC (MOI = 0.1). RNAs were analyzed by RT-
PCR as described in A). Arrows indicate the predicted size of the
principle splice products. C) Ae. albopictus C6/36 cells were
transformed with group I intron vector constructs and maintained
under hygromycin selection. Transformed cells were washed three
times and challenged with DENV 2-NGC (MOI 0.01). Infections were
allowed to proceed for 4 days, supernatants were collected, and
viral titers were determined by TCID50-IFA as described in Methods.
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limited mismatching of the RISC complex RNA to its
target is tolerated to a degree [11]. In contrast, the abil-
ity of an induced RNAi response to discriminate
between different alleles of the same gene varying only
by a single nucleotide has also been observed [43].
W h e t h e ro rn o tap a r t i c u l a rm u t a t i o nw i t h i nt h et a r -
geted region confers resistance appears to depend on
the location of the altered base as well as the nature of
the alteration itself. Selective pressure within the cells of
a mosquito may initially silence a Dengue infection, but
eventually that pressure would serve to promote the
replication of virus genomes carrying mutations confer-
ring resistance to the RISC complex nuclease activity.
Such mutants would be transmitted by the insect and
spread throughout a population even in the presence of
the protective measures granted by RNAi, eventually
rendering the specific sequence utilized in priming a
mosquito for an RNAi response useless in the face of
the escape mutant strain of Dengue.
The experiments presented here are not conducted
i naw a yt h a to n ec a na s s e s si ft h eG r p - 1a p p r o a c hi s
superior or inferior to siRNA/shRNAs. siRNA does not
carry out splicing, and our research was meant to
establish that we had successfully designed GrpI
introns that do target and splice conserved sequences.
Further, an abundance of siRNA work has already
been performed with DENV [44,45] and this sequence
is not among those identified as useful for targeting
because the length of conservation for this sequence
among all DENV is smaller than required for an
siRNA response.
Group I trans-splicing introns have a demonstrated
potential for targeting RNA virus genomes in infected
cells [20,21]. In this report we demonstrate the feasibil-
ity of using aDENV-GrpIs to catalyze trans-splicing of
the 5’ conserved region of the DENV family genomes.
In designing Group I intron splicing approaches most
studies employ a GN5 library scan to map those uracils
most accessible to trans-splicing in an otherwise highly
invariant sequence [28]. The highly mutable nature of
the Dengue genome precludes this approach, as any ura-
cils identified may or may not be present in other sero-
types or even other strains of the same serotype.
In addition to the questionable presence of the uracil,
the immediate neighboring sequence must also be con-
served to facilitate targeting through base pairing inter-
actions. We determined our optimal Group I intron
target following alignment of 98 instances of DENV
from GenBank which identified one conserved region
that appeared to satisfy the requirements for trans-
splicing within the DENV genome. This region is
positioned within the capsid coding sequence at nucleo-
tides C131 to G151 [23,25], and contains a number of
possible uracil targets for the trans-splicing reaction.
This region is a part of a double-stranded 5’-3’CS
domain that forms as a result of complementary base
pairing between the proximal ends of the 5’ and 3’
UTRs during DENV replication [23]. The formation of
the 5-3’CS domain has been shown to be essential for
DENV replication [25]. We designed anti-DENV Group
I trans-splicing introns (aDENV-GrpIs) to target two of
these uracil bases within the identified conserved region,
U143 and U132.
Intron 9v1, which has a 9 base P1 helix, and a 9 base
EGS (Additional file 1), is designed to effectively
trans-splice all known DENV sequences. This intron
demonstrated an ability to cleave at U143 and effectively
trans-splice an infecting DENV 2 NGC genome either
upon transfection of Aag2 cells or as a constitutively
expressed RNA in transformed C6/36 cells.
A separate set of aDENV-GrpIs were constructed with
an extended 96 base antisense EGS that was engineered
to target the DENV-2 NGC (Figure 1b). Each version of
this series shares the same EGS and P1 helix, and tar-
gets U132, but differs in their P10 helix. 96v1 has a 6
base pair P10 helix with no wobble base, and a standard
P1 helix including the required wobble base (Additional
file 1). 96v3 differs from 96v1 in trimming of 3 nucleo-
tides between the P10 helix and the catalytic core, while
96v4 incorporates a wobble base pairing downstream of
the 3’ exon splice-site.
Each aDENV-GrpI was constructed with a 3’ firefly
luciferase (FL) ORF that permitted quantitative assess-
ment of splicing activity. Co-transfection assays for FL
activity were performed in S2 or Aag2 cells using the
fold back DENV-2 mimic plasmid and either BQCV or
DCV IRES/mCherry-linked aDENV-GrpI 9v1 or
96v4expression plasmids introns. Although all introns
assayed exhibited firefly luciferase activity, aDENV-GrpI
as96v4 displayed the greatest amount of luciferase activ-
ity, and therefore the greatest amount of trans-spliced
product. This is likely due to both the relative activity of
the intron configuration as well as an increased effi-
ciency of targeting as a result of the extended EGS. The
aDENV-GrpI as9v1, designed to target all DENV sero-
types, also displayed a significant ability to successfully
splice our DENV mimic in these cells, but its reduced
level of FL activity reflectsas o m e w h a tr e d u c e de f f i -
ciency of targeting relative to aDENV-GrpI as96v4. This
is likely due to the presence of a shorter EGS, as this
has been previously shown to decrease the ability of a
trans-splicing intron to attack a target sequence [7].
Alternatively, the relative effectiveness of cleavage for
U143 targeted by the 9v1 intron may be less than that
for U132 targeted by the 96v4 introns. Nonetheless, this
intron was still quite effective in targeting and splicing
the DENV sequence.
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fected with these aDENV GrpI constructs were chal-
lenged by infection with DENV-2 NGC. These results
validated the potential of our aDENV-GrpI intron
approach as an effective means of suppressing DENV
infection of mosquito cells and tissues.
We also observed that addition of a 3’ IRES/mCherry
configuration, whether incorporating the BQCV IRES or
the DCV IRES, does not appear to alter the trans-spli-
cing capabilities of either intron, Because the IRES
allows expression of the mCherry fluorescence marker
in the unspliced intron, this provides a convenient inde-
pendent marker for determining the relative efficiency
of expression of the introns following transfection.
The potential of these intronc o n s t r u c t st of u n c t i o ni n
transformed mosquito tissues was confirmed by demon-
strating their activity against infectious DENV-2 NGC in
transformed C6/36 cells expressing the bicistronic
aDENV-GrpIs 9v1 or 96v4, either linked with the BQCV
or DCV IRES driven mCherry, or lacking an IRES
mCherry linkage (Figure 7). RT-PCR amplified DENV-2-
FL splice product confirms the ability of both aDENV
G r p I9 v 1a n d9 6 v 4c o n s t r u c t si nt a r g e t i n gD E N V - 2
NGC. A decreased band intensity of the DENV-2-FL
splice product was obtained with aDENV-GrpI 9v1 com-
pared to that resulting from aDENV-GrpI 96v4 activity,
and may once again be due to differences in the lengths
EGS of these two introns since EGS length is a determin-
ing factor for GrpI trans-splicing efficiency [7].
Further validation of these introns as potent tools to
combat DENV is evidenced by TCID50-IFA analyses
that test suppression of overall infectious virus produc-
tion (Figure 7). A 2 log (for 9v1) to 3 log (for 96v4) was
observed demonstrating these aDENV-GrpIs do sup-
press DENV 2-NGC infection of the transformed cells,
and the aD E N V - G r p I9 v 1 ,d e s i g n e dt ot a r g e ta l lf o u r
Dengue serotypes, has the ability to suppress the replica-
tion of all serotypes of this virus.
Conclusions
The results presented here show that the 9v1 intron,
designed to be active against all forms of Dengue virus,
is capable of effectively targeting the DENV 2-NGC gen-
ome in a sequence specific manner, while suppressing
virus production. These novel aDENV-GrpIs provide an
attractive alternative to other RNA based approaches for
the transgenic suppression of DENV in transformed
mosquito cells and tissues.
Methods
Alignment of all DENV genomes
DENV sequence data was obtained from the national
center of biotechnology information (NCBI). Sequences
representative of all four serotypes of Dengue were
aligned using ClustalX [46]. The aligned sequences com-
prise the following GenBank GenInfo identifiers:
12018173, 12018169, 12018171, 12659201, 2909798,
2909788, 2909786, 2909796, 6841603, 6841595,
6841605, 6841591, 6841601, 6841597, 6841593,
6841599, 6841587, 6841585, 6841589, 1000740,
1000738, 2909784, 1000736, 4926937, 4926935,
4926927, 4926929, 4926931, 2909794, 2909792,
1000742, 4926933, 2155257, 2723944, 323447, 6581076,
6581078, 2723942, 323449, 323650, 18644123, 1864412,
11119731, 19744844, 18644125, 18644127, 18643733,
4337012, 13386495, 1881708, 19071809, 13926152,
9280544, 14585842, 4926947, 4926939, 323654,
4926945, 4926943, 7329983, 7329981, 13540386,
14328931, 14485523, 323660, 17129645, 22901065,
22901063, 22901061, 1854040, 1854038, 1854036,
17129647, 24417519, 24417517, 24417515, 27656962,
24417513, 19071807, 14195698, 8927332, 14328929,
12711599, 323468, 25992053, 25992047, 25992041,
25992029, 25992025, 25992055, 25992033, 19071811,
25992043, 25992039, 25992037, 25992051, 25992031,
and 25992057.
Cells, Virus and Antibody
The Drosophila melanogaster In S2 cells, obtained from
ATCC, were maintained in Schneider’s Modified Droso-
phila media (Invitrogen/Gibco) 10% FBS (Atlanta Biolo-
gicals), penicillin G (100 U/ml; Invitrogen/Gibco) and
streptomycin (100 μU/ml; Invitrogen/Gibco). Aag2
Aedes aegypti mosquito cells (a kind gift from Dr. Ken
Olson, Colorado State University, Fort Collins, CO)
were maintained in Schneider’sM o d i f i e dD r o s o p h i l a
media (Lonza Group Ltd., Walkersville, MD, USA) sup-
plemented with 10% FBS, 2 mM glutamine, penicillin G
and streptomycin as described for the S2 cells used in
this study. Both cell types were maintained in a 28°C/5%
CO2 environment.
T h eD e n g u e2p r o t o t y p ev i r u sN e wG u i n e aCs t r a i n
(DENV2-NGC; a kind gift from Dr. Stephen Higgs,
UTMB, Galveston, TX) was used in this study. Viral
stocks were prepared as follows. Aag2 cells were
infected with DENV 2-NGC. At 7 days post-infection,
cells were scraped and freeze-thawed for three (3)
cycles. Cell debris was removed by spinning cell suspen-
sions at 10000 RPM for 30 min, and aliquots of 100 ul
were stored at -80°C until used, one aliquot was
used for determining the TCID 50 of the stock. This
virus stock (TCID 50 =1 0
7) was used in subsequent
experiments.
Design and assembly of anti-Dengue virus group I intron
constructs
All primer sequences are illustrated in Additional file 2.
All PCR products described here were band isolated
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or the Wizard SV Gel and PCR Cleanup Kit (Promega)
and used as templates for a second round of PCR with
the same primers used for the initial PCR reactions and
Platinum Pfx high-fidelity DNA polymerase according to
the manufacturer’s protocols in order to minimize the
amount of contaminating circular plasmid. Following
band isolation all PCR products were digested with
restriction endonucleases, obtained from New England
Biolabs (NEB). All vectors were Antarctic phosphatase
treated (NEB) prior to ligation. The final constructs pro-
duced were sequenced and restriction digested to verify
plasmid integrity and presence of the inserts.
pA5c backbone
The aDENV-GrpI were cloned into an expression vec-
tor under the control of the distal Drosophila melanoga-
ster actin5c. The actin5c promoter was PCR amplified
from the plasmid pHermes [Actin5c:EGFP] [47].’ Fol-
lowing band isolation the PCR product and the vector
pBlueScriptII SK+ (Stratagene, La Jolla, CA) were band
isolated and digested with the restriction enzymes
Acc65I and NotI, and ligated using T4 DNA ligase
(NEB) to give the plasmid pBlueScriptII SK+ Actin5c
(pBSII-A5c). The SV40 late transcription terminator and
polyadenylation signal was amplified from the plasmid
pMT/V5-HisA (Invitrogen). The SV40 PCR product and
pBSII-A5c were digested with NotI and SacI (NEB). The
plasmid and insert were ligated together with T4 DNA
ligase to yield the vector pA5c, and served as the back-
bone for the rest of the plasmids produced unless other-
wise noted.
pA5c-FL
The firefly luciferase open reading frame was PCR
amplified from the vector pGL-Basic (Promega). The
PCR product and pA5c vector were a digested with
XhoI and NotI. and ligated to yield pA5c-FL.
Group I introns
All introns were derived from the catalytic core of the
rRNA Tetrahymena thermophila group I intron on the
pTT1A3-T7 plasmid (Kind gift of Dr. Thomas R.
Cech; [48]). The 9 series aDENV-GrpIs Δ9a n d9 v 1a s
well as the 96 series Δ96 96v1, 96v3, and 96v4, were
generated by PCR amplification of the rRNA Tetrahy-
mena thermophila group I intron using the primer sets
shown in Additional file 2. Following PCR amplifica-
tion and band isolation the aDENV-GrpIs were
digested with MluI and XhoI and inserted into pA5c-
FL. The intron designated 9v1 for the length of its
antisense region, was amplified, inserted into pA5c-FL,
and named pA5c-9v1.
The 96 series introns were all PCR amplified in two
steps. An initial PCR template was created by amplifica-
tion of pTT1A3-T7 with an initial primer set (see 96
series primer set 1 in ST1) and used as a template for a
second round of PCR. For this second PCR step each 96
series was amplified with the same forward primer used
in the first PCR step, but with different reverse primers
for each 96 series intron (see ST1, “96 series primer set
2”). The resulting introns were named pA5c-96v1,
pA5c-96v3, and pA5c-96v4.
ΔP5abc Introns
To create introns missing the P5abc helix, the catalytic
core of the intron was first amplified from pTT1A3-T7
and then inserted into the vector pCR2.1-Topo (Invitro-
gen) to create pCR2.1-GI. Using opposite facing primers
5’ 3’ and with the BsmBI restriction site at each of their
5’ ends, the entire pCR2.1-GI vector containing the
intron was amplified, save for the P5abc helix. The
resulting PCR product was purified, digested with
BsmBI and DpnI and ligated to itself to form the plas-
mid pCR2.1-ΔP5GI, which contained the catalytic core
of the intron without the P5abc helix.
For purposes of creating control vectors, the intron
fragments from plasmid pCR2.1-ΔP5GI were amplified
with the same primers as the intron inserts from the
9v1, 96v4 series as described above. The products were
band isolated and digested with MluIa n dXhoI, and
inserted into the pA5c-FL using the same restriction
sites yield pA5c-Δ9v1 and pA5c-Δ96v1, respectively.
Evaluation of aDENV-GrpIs in S2 cells necessitated
the construction of double and single-stranded DENV
2-NGC target constructs. The assembly of these is
detailed below.
pA5c-EYFP
The DENV 2-NGC target carrier plasmid, pA5c-EYFP,
was created by amplification of the EYFP open reading
frame from pXL-Bac-EYFP [49]. The PCR product was
band isolated and digested with MluIa n dXhoI, and
inserted into the pA5c-FL plasmid using these same
sites.
pA5c D2EYFP single stranded target plasmid
The yeast shuttle vector pRS424-DENV-2 NGC (a kind
gift of Dr. Barry Falgout) was used as the template
for PCR amplification of substrate fragments for the
production of the single stranded DENV 2-NGC target
substrate. PCR products corresponding to nucleotides
85-267 of the DENV 2-NGC genome were digested with
the restriction enzymes BssHII and MluI, and inserted
into the MluI digested pA5c-EYFP.
pA5c-D2EYFPD2 double stranded target plasmid
The substrate plasmid bearing the hybridizing sections
of the DENV-2 NGC genome at either end of an EYFP
open reading frame was made by amplification of the 3’
terminus (nt10495-10723) of the DENV-2 NGC genome
from pRS424-DENV-2 NGC. The PCR fragment frag-
ment was digested with the restriction enzymes XhoI
and XbaI and inserted into the XhoI, XbaId i g e s t e d
pA5c-D2EYFP plasmid.
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The Renilla luciferase normalizing plasmid was created
by PCR amplification of the chimeric intron and Renilla
luciferase open reading frame from the plasmid pRL-
SV40 (Promega). Following band isolation, PCR frag-
ments were digested with XhoIa n dNotIa n di n s e r t e d
into the XhoI and NotI-digested pA5c plasmid.
pA5c-DNA+ctrl The plasmid directing the constitutive
expression of an mRNA corresponding to the predicted
trans-spliced product was made by amplification of the
DENV-2 fragment from the pA5c-D2-EYFP plasmid fol-
lowed by digestion of the PCR fragment and the vector
pA5c-FL with NotIa n dXhoI, and ligation of these
fragments.
BQCV and DCV-mCherry bearing aDENV-GrpIs
Production of aDENV-GrpI constructs possessing either
the BQCV or DCV intergenic IRES sites linked to an
mCherry fluorescent marker was achieved through the
insertion of PCR amplified BQCV-mCherry or DCV-
mCherry fragments into the pA5c-9v1 and pA5c-96v4
plasmids immediatelyu p s t r e a mo ft h e3 ’ exon, FL
(Figure 4a). The BQCV-mCherry and DCV-mCherry frag-
ments were derived unpublished vectors, pA5c-BQCV-
mCherry an pA5c-DCV-mCherry. Prior to insertion PCR
amplified BQCV-mCherry and DCV-mCherry fragments
as well as the 9v1 and 96v4 bearing constructs were
digested with NotI and BamHI. The IRES-linked mCherry
PCR fragments were then ligated into the vector
constructs.
Reverse transcription-PCR of DENV 2-firefly luciferase
splice products derived from cell culture
T h et o t a lR N Af r o mD e n g u ev i r u si n f e c t e da n du n i n -
fected cells was extracted using the Qiashredder and
RNeasy Mini kits (QIAGEN Inc., Valencia, CA, USA) in
accordance with the manufacturer’si n s t r u c t i o n sa n d
eluted in a final volume of DNAse/RNAse free water to
a final volume of 40 μl. The total RNA (5 ug) extracted
was treated with 2 U Turbo DNA-free DNAse (Applied
Biosystems/Ambion, Inc. Austin, TX USA) to rid sam-
ples of any DNA contamination, 30 minutes at 37°C.
For DNase inactivation, 0.2 volumes of DNase Inactiva-
tion Reagent (Applied Biosystems/Ambion, Inc. Austin,
TX USA) was added to each sample tube and incubated
at room temperature for 5 minutes, mixing occasionally.
One-step RT-PCR was performed using the SuperScript
III One-Step RT-PCR kit (Invitrogen) in accordance
with the manufacturer’s instructions. cDNA synthesis
and PCR amplification were performed as follows: 1)
cDNA synthesis at 50°C for 45 minutes, 2) 40 cycles:
denaturation at 95°C for 2 minutes, annealing at 60°C
for 1 min, and extension at 68°C for 2 min, 3) final
extension of 68°C for10 minutes. For detection of the
DENV-2 NGC- FL spliced product the forward primer
5’ TCTGATGAATAAC 3’, designed to anneal to
DENV2- NGC, and the reverse primer 5’ GAACGTG-
TACATCGACTGAAATCC 3’, designed to anneal to FL
were used.
Luciferase assays
Schneider 2 (S2) cells were plated into 9.6 cm
2 well in
minimal S2 media (Gibco) at a density of 1.0 × 10
6cells/
well. Following the adherence of cells, 3 μg intron, 1 μg
double-stranded DENV2 target, and 0.05 μgo fI R L
expression plasmids were co-transfected into the cells
using the Transfectin liposomal transfection reagent
(Bio-Rad Laboratories, Hercules, CA) in accordance
with the manufacturer’s protocol. Transfected cell were
incubated at 28°C/5%CO2 for 16 hours, washed once in
Schneider’s media and once in Schneider’sm e d i as u p -
plemented with 10% FBS and penicillin/strepavidin.
These cells were overlaid with Schneider’s media supple-
mented with 10% FBS, 25 μg/mL amphotericin and
penicillin/strepavidin, and incubated at 28°C with 5%
CO2 for 72 hours. Following this incubation period cells
were gently rinsed twice with 1 ml of 1×PBS pH7.4, and
harvested in 300 μl of 1× passive lysis buffer (Promega).
The lysates were spun and the supernatants were moved
to new tubes. Ten microliters of the supernatant from
each tube was added in triplicate wells of a 96 well
microtiter plate in and analyzed using the Dual Lucifer-
ase System (Promega) with an LMaxII
384 Luminometer
(Molecular Devices, Sunnyvale, CA) with the following
parameters: 10 μl of each substrate,2 second delay, 5
second reading integration. Firefly luciferase readings
were normalized against the Renilla luciferase reading
by dividing the firefly raw data by the amount of Renilla
luciferase detected.
Aag2 cells were plated into 9.6 cm
2 well in minimal
S2 media (Lonza) at a density of 1.0 × 10
6cells/well. At
15 hours post- plating cells were transfected as per-
formed for S2 cells. Following an overnight incubation
(16 hours), cells were washed once with 1 ml Schneider’s
minimal media and once with 1 ml infection media
(Schneider’s media containing 2% FBS and 1% essential
amino acids). Cells were then overlaid with 2 ml infection
media containing DENV-2 at an MOI of 0.01, gently
rocked for 1 hr to aid in absorption of the virus, then
incubated at 28°C with 5%CO2 for 96 hours. Cells were
processed and analyzed for luciferase activity as described
for the S2 cells above. All luciferase experiments were
performed in triplicate.
TCID50-IFA analysis
Assessment of DENV-2 NGC titre was measured using
serial 10 fold dilution followed by detection of the cell
surface expressed DENV E protein as previously
described [4]. Briefly, cell media containing virus from
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overlaid onto naive C6/36 cells using 10 fold serial dilu-
tions in a 96 well plate and incubated for 4 days at 28°C
without CO2. Cells were then fixed with acetone:DPBS
(3:1) and stained with a primary DENV envelope (E)
antibody (1:200) [50]. Positive DENV-2 NGC infected
cells were detected using a biotinylated-streptavidin
detection system conjugated with Fluorescein isothiocya-
nate (FITC; Amersham Biosciences, Piscataway, NJ). Cell
cytoplasms displaying fluorescence were scored as posi-
tive for DENV infection. The number of positive wells
were counted and the virus titers calculated according
to Karber’s method [51].
Additional material
Additional file 1: Sequence composition of the aDENV-GrpI. The
features of each aDENV- GrpI are shown and construction is described in
Methods. Right column lists the individual aDENV-GrpIs used in this
study. The nucleotide sequences of each region are listed beside the
corresponding aDENV-GrpI. Internal guide sequence = IGS, BL = bulge
loop, External guide sequence = EGS, P10 = P10 helix.
Additional file 2: Primers and PCR fragments. The forward and
reverse primer sets used to produce the corresponding PCR fragments
are listed. Restriction sites are in lower case text. See Methods for
description of vector constructs.
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